Zentalis Pharmaceuticals Announces Pricing of $80.5M Public Offering
Zentalis Pharmaceuticals priced an underwritten public offering of 23,000,000 shares of common stock at $3.50 per share, aiming for approximately $80.5 million in gross proceeds. According to BioSpace, the capital … Read More